Loading...

Blue Dogs Lead Bipartisan Effort to Lower Prescription Drug Costs, Increase Transparency

March 27, 2019 by Dan McCue
Blue Dogs Lead Bipartisan Effort to Lower Prescription Drug Costs, Increase Transparency

The Blue Dog Coalition on Wednesday threw its support behind two bipartisan bills that aim to lower prescription drug costs and increase transparency in the drug pricing system.

The coalition is a House caucus of moderate and fiscally responsible Democrats. The bills they endorsed are the Payment Commission Act and the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act.

Both pieces of legislation are being marked up by the House Energy and Commerce Committee this week.

“In this era of divided government, the only way we can fully address the issues impacting the American people is to find a bipartisan solution that can be implemented into law,” said Rep. Tom O’Halleran, D-Ariz., the Blue Dog co-chair for policy.

“The rising cost of prescription drugs is forcing hardworking families to choose between life-saving medication and other necessities,” he continued. “Congress must act to bring those prices down and increase transparency surrounding drug pricing. Today, the Blue Dogs have come together to address this problem by supporting bipartisan legislation that does just that.”

The Payment Commission Act provides Congress’ independent advisory bodies, the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission, access to certain drug pricing data that will help them formulate recommendations on how to improve the Medicare and Medicaid programs and lower prescription drug prices.

The Act was introduced by O’Halleran and with Representatives Earl L. “Buddy” Carter, R-Ga., Tom Rice, R-S.C., and Jimmy Panetta D-Calif., who believe the legislation will lead to meaningful policy reforms that will ultimately help patients.

Meanwhile, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act, introduced by Blue Dog Co-Chair Representative Kurt Schrader, D-Ore., and Georgia’s Carter, aims to keep drug prices down by increasing competition in the generic drug market.

Currently, drug manufacturers are guaranteed 180 days of market exclusivity when they are the first to file a generic drug application with the FDA.

Intended to reward manufacturers for bringing new low-cost drugs to the market, the current legislative regime includes a flaw that effectively stymies competition.

The 180 days of market exclusivity begin once the first to file manufacturer starts marketing their drug, but even before the first to market begins marketing, all other generic competitors are blocked from coming to market.

This allows manufacturers to “park” the exclusivity before receiving final approval, blocking competition for more than the 180 days intended by the law, the Blue Dog Coalition said.

In these cases, no other generics can come to the market until the first manufacturer receives final approval, begins marketing the drug, and the subsequent 180 days have passed.

The BLOCKING Act would stop such first generic drug “parking” by mandating that if a second generic drug application is blocked from approval solely due to a first generic drug manufacturer parking their exclusivity at the tentative approval stage, the 180 days immediately begins to run, preventing limitless delays.

The legislation mirrors a proposal to “speed development of more affordable generics to spur competition” that was included in the Trump administration’s FY2019 budget proposal.

“Too many patients across this country feel a severe impact from rising drug prices, often on prescriptions they’ve been filling for years,” Representative Schrader said.

“I have long said there is not one silver bullet solution to this crisis, however, we do know that increasing competition on the drug market places a check on manufacturers and keeps costs down,” he continued. “My bill is one such solution that targets and eliminates unnecessary delays in allowing more drugs on the market, ensuring that manufacturers are still incentivized to produce more drugs and that markets continue to see robust competition.”

In The News

Health

Voting

Health

May 18, 2022
by Alexa Hornbeck
CalAIM Launches Program to Reform Housing and Health Care Coverage in California  

A new program launched this year out of California called CalAIM helps high-risk and low-income Medi-Cal residents find affordable housing... Read More

A new program launched this year out of California called CalAIM helps high-risk and low-income Medi-Cal residents find affordable housing through their health insurance plans. The CalAIM program is intended to improve health outcomes of Medi-Cal enrollees, specifically those with behavioral health needs, seniors, people living... Read More

May 18, 2022
by Alexa Hornbeck
Smart Pacifier Provides Non-Invasive Way to Monitor Babies’ Electrolytes in Hospitals

Researchers from Washington State University released a study on Monday regarding their development of a smart pacifier that can be used to... Read More

Researchers from Washington State University released a study on Monday regarding their development of a smart pacifier that can be used to monitor infant health in hospitals. The wireless, bioelectronic pacifier will eliminate the need for invasive, twice-daily blood draws to monitor babies’ electrolytes in newborn intensive care... Read More

May 18, 2022
by Alexa Hornbeck
WHO and UNICEF Release Report on Role of Assistive Technologies 

The World Health Organization and UNICEF released a report on Monday that finds more than 2.5 billion people need one or more... Read More

The World Health Organization and UNICEF released a report on Monday that finds more than 2.5 billion people need one or more assistive products, such as wheelchairs, hearing aids or apps that support communication and cognition.  Despite the need, nearly 1 billion are denied access to such technologies,... Read More

May 18, 2022
by Alexa Hornbeck
House Committee Advances Legislation for Medication Access and Training for Opioid Addiction 

During a mark-up session on Wednesday, the House Energy and Commerce Committee voted to advance provisions of the Medication Access and Training... Read More

During a mark-up session on Wednesday, the House Energy and Commerce Committee voted to advance provisions of the Medication Access and Training Expansion Act, known as the MATE Act. The legislation is designed to ensure controlled medication prescribers have a baseline knowledge of how to treat patients suffering with... Read More

May 18, 2022
by Alexa Hornbeck
FDA Approves First At-Home Test for Detecting COVID, Flu and RSV

The U.S. Food and Drug Administration authorized the first at-home test that can identify and differentiate multiple respiratory viruses at... Read More

The U.S. Food and Drug Administration authorized the first at-home test that can identify and differentiate multiple respiratory viruses at the same time, detecting influenza A and B, respiratory syncytial virus and SARS-CoV-2, the virus that causes COVID-19.  “While the FDA has now authorized many COVID-19... Read More

May 18, 2022
by Alexa Hornbeck
Study Shows Link Between Arthritis Pain and Mental Health

The Arthritis Foundation released new findings on May 17 showing a link between emotional support and well-being and arthritis pain. The Center... Read More

The Arthritis Foundation released new findings on May 17 showing a link between emotional support and well-being and arthritis pain. The Center for Program Design and Evaluation at Dartmouth College conducted the analysis using data from nearly 27,000 patient responses collected from 2019 to 2022 from the Arthritis... Read More

News From The Well